Central retinal vein occlusion
Central retinal vein occlusion is much more common than central retinal artery occlusion. Although visual impairment is not as dramatic as artery occlusion, it is also quite serious. In some cases, complete blindness may occur due to secondary neovascular glaucoma.
-
Site of disease:
Eye -
Infectious :
Not contagious -
Frequent population:
Middle-aged and elderly people -
Related symptoms:
Visual impairment retinal hemorrhage and exudation retinal vein tortuosity and dilation vitreous blood stains retinal hemorrhage -
Concurrent disease:
Related Drugs
Xueshuantong injection
Manufacturer:
Guangdong Leiyunshang Pharmaceutical Co., Ltd.
Xuesetong Injection
Manufacturer:
HeiLongJiang ZBD Pharmaceutical Co., Ltd.
Xuesetong Injection
Manufacturer:
Xi`an Han Feng Pharmaceutical Co., Ltd.
Xuesetong Injection
Manufacturer:
Hubei Tiansheng Pharmaceutical Co., Ltd.
Xuesetong Injection
Manufacturer:
Jiangsu Langou Pharmaceutical Co., Ltd.
Total saponins of Panax notoginseng
Indication: It can promote blood circulation, remove blood stasis, and dredge meridians. It has the effect of inhibiting platelet aggregation and increasing cerebral blood flow. It is used for cerebrovascular sequelae, central retinal vein occlusion, anterior chamber hemorrhage, etc.
Xuesetong Injection
Manufacturer:
Bikang Pharmaceutical Xinyi Group Holdings Co., Ltd.
Xuesetong Injection
Manufacturer:
Bikang Pharmaceutical Xinyi Group Holdings Co., Ltd.
Related Ingredients
-
Ginsenoside Rb1 list
41753-43-9 -
Ginsenoside Rg1 list
22427-39-0 -
Notoginsenoside R1 list
80418-24-2